![Jian Li](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jian Li
Director/Board Member at Shanghai Drug Farm Biological Technology Co., Ltd.
Profile
Jian Li currently works as a Director at Shanghai Drug Farm Biological Technology Co., Ltd.
Jian Li active positions
Companies | Position | Start |
---|---|---|
Shanghai Drug Farm Biological Technology Co., Ltd.
![]() Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Shanghai Drug Farm Biological Technology Co., Ltd. is a Chinese private biotechnology company that focuses on developing innovative treatments for hepatitis B, heart and kidney diseases, and ROSAH syndrome. The company utilizes breakthrough technologies in genetics and AI to discover new treatments through its unique IDinVivo platform. This platform allows the direct assessment of gene targets in living animals with intact immune systems, which has led to the identification of novel innate immunity pathways and targets. Drug Farm is now advancing multiple first-in-class drug candidates into clinical development. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Shanghai Drug Farm Biological Technology Co., Ltd.
![]() Shanghai Drug Farm Biological Technology Co., Ltd. Information Technology ServicesTechnology Services Shanghai Drug Farm Biological Technology Co., Ltd. is a Chinese private biotechnology company that focuses on developing innovative treatments for hepatitis B, heart and kidney diseases, and ROSAH syndrome. The company utilizes breakthrough technologies in genetics and AI to discover new treatments through its unique IDinVivo platform. This platform allows the direct assessment of gene targets in living animals with intact immune systems, which has led to the identification of novel innate immunity pathways and targets. Drug Farm is now advancing multiple first-in-class drug candidates into clinical development. | Technology Services |
- Stock Market
- Insiders
- Jian Li